Advances in urothelial cancer treatment and prognosis

Expert-led insights from the 2023 ASCO® GU Cancers Symposium

Advances in urothelial cancer treatment and prognosis: Expert-led insights from the 2023 ASCO® GU Cancers Symposium

Tuesday 7th March, 10:30 CET | 12:30 TRT | 15:00 IST | 17:30 Singapore

International experts in bladder cancer will explore clinical outcomes and endpoints of interest in locally advanced muscle-invasive, and metastatic urothelial cancer in the following pivotal studies:

  • IMvigor130
  • CheckMate 274
  • UNITE
  • HCRN GU 16-257
  • HCRN GU14-188
  • TROPHY-U-01
Enrique Grande, MD, PhD, MSc

CHAIR

Enrique Grande, MD, PhD, MSc

Enrique Grande, MD, PhD, MSc

Enrique Grande, MD, PhD, MSc

MD Anderson Cancer Center, Madrid

Dr. Enrique Grande is Director of the Medical Oncology Program and Clinical Research lead at the MD Anderson Cancer Center, Madrid. Dr. Grande’s research is focused on Genitourinary and Endocrine tumors, which involves active collaboration with the Translational Research and Early Drug Development Unit. He has a publication history of more than 200 manuscripts in peer-reviewed journals. Dr. Grande is also the founder of the Spanish Group for Research on Orphan and Uncommon Tumours (GETHI). Dr. Grande is an Editor of several international journals and has participated in the most recent trials in the field of bladder cancer and co-chairs the steering committee of the IMVIGOR-130 trial.

Faculty

Ravindran Kanesvaran, MD, MRCP(UK), FAMS (Med Oncol)

National Cancer Centre, Singapore

Associate Professor Ravindran Kanesvaran is Senior Consultant and Deputy Chair of the Division of Medical Oncology of the National Cancer Centre, Singapore. He is also an Associate Professor at Duke-NUS Graduate Medical School. He is actively involved in graduate medical education and is the Programme Director of the Medical Oncology Senior Residency Programme. His research interests include genitourinary (GU) oncology and geriatric oncology. He has also been awarded a number of awards including the ASCO GU Merit Award 2009, American Association for Cancer Research (AACR) scholar-in-training Award 2010 and ESMO Fellowship Award 2012. He is currently the immediate past President of the Singapore Society of Oncology and the Singapore Geriatric Oncology Society. He is the President of the International Society of Geriatric Oncology. He was also awarded the Singhealth Excellent Service Quality Award in 2018 (Silver), 2019 (Gold), and 2022 (STAR). He is vice-chair of the Singapore Cancer Society. He was recently awarded the National Commendation Medal 2022 for his contribution to COVID-19 work.

Reserve your place

After registering we’ll provide you with:

Funding

This independent medical education meeting has been funded by Astellas. Astellas has provided funding for speaker fees, organisational costs, plus the venue. The views and opinions expressed in this independent presentation belong solely to the author. The contents of this presentation do not constitute an endorsement of the use of any product by Astellas or necessarily represent the views of Astellas.